Catalyst Pharmaceuticals (CPRX) Citi's 2024 Global Healthcare Conference summary

Panel introductions and company overviews

• Panel featured leaders from three companies focused on neuromuscular disorders, each with distinct business models and drug development strategies.

• One company operates as a commercial-stage buy-and-build organization with marketed drugs for rare CNS and muscle disorders, including a recent launch for Duchenne muscular dystrophy (DMD).

• Another is a development-stage RNA medicines company leveraging proprietary chemistry for allele-specific therapies and RNA editing, with programs in Huntington's, DMD, alpha-1 antitrypsin deficiency, and obesity.

• The third focuses on precision genetic medicines for cardiac and neuromuscular targets, with clinical-stage DMD programs and a new collaboration for cardiac gene therapies.

DMD therapeutic landscape and future directions

• Panelists discussed complementary approaches to DMD, including exon skipping, microdystrophin gene therapy, and corticosteroids, emphasizing the potential for combination therapies.

• Advancements target both ambulatory and non-ambulatory patients, with focus on early intervention and preservation of muscle, cardiac, and respiratory function.

• Novel delivery technologies, such as engineered capsids and proprietary oligonucleotide chemistries, are improving tissue targeting and therapeutic durability.

• Redosing strategies and next-generation capsids are being developed to overcome immune barriers and enhance efficacy.

• All panelists highlighted the importance of collaboration and innovation to address the wide variability and unmet needs in DMD.

Regulatory environment and clinical development

• Regulatory agencies are increasingly open to flexible endpoints, surrogate biomarkers, and accelerated approval pathways for neuromuscular and rare diseases.

• Real-world evidence and patient-centric outcomes are being incorporated into trial designs, especially for populations where traditional endpoints are less feasible.

• Recent agency communications reaffirm support for next-generation gene therapies and individualized program assessments.

• Companies are pursuing both US and ex-US regulatory strategies, including double-blind placebo-controlled trials for global reimbursement.